Curidium trademarks PsychINDx name for schizophrenia/bipolar disorder test:
This article was originally published in Clinica
Executive Summary
London, UK-based personalised medicine company Curidium has filed worldwide trademark applications confirming PsychINDx as the name for its blood diagnostic test designed to classify patients with schizophrenia or bipolar disorder into four separate subgroups. The company claims that PsychINDx could improve treatment of these patients and aid the development of new drug treatments for these disorders. The global market for antipsychotics used in the treatment of these two illnesses was valued at $12.5bn in 2004 and is expected to grow to $20.5bn by 2009, according to Curidium.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.